Circular Genomics

Jul 08, 2025

Circular Genomics Receives $250K Investment from the Alzheimer's Drug Discovery Foundation (ADDF) to Advance First-in-Class Circular RNA Blood-Based Biomarker Tests for the Early Detection of Alzheimer's Disease

Jun 18, 2025

Circular Genomics Announces Formation of its Commercial Advisory Board with Veteran Industry Leaders

Mar 17, 2025

Circular Genomics Joins Lilly Gateway Labs in San Diego to Develop Its Best-In-Class Circular RNA Platform for the Diagnosis and Prognosis of Alzheimer's Disease

Sep 16, 2024

Circular Genomics Announces Launch of MindLight(TM), the First SSRI Antidepressant Response Test Using Brain-Derived Biomarkers

May 07, 2024

Circular Genomics Announces New Research Demonstrating Accuracy of circRNA-based Test for Predicting Response to SSRI Antidepressant Treatment

Mar 18, 2024

Circular Genomics Adds Dr. Michael Ackermann, PhD, MBA to its Scientific Advisory Board

Feb 26, 2024

Circular Genomics Strengthens Leadership Team with Key Commercial and Research Hires